Add BrightSurf on Google Email

New front line treatment for advanced colorectal cancer

Researchers at Memorial Sloan-Kettering Cancer Center developed a new combination therapy of irinotecan, fluorouracil, and leucovorin that nearly doubled the tumor response rate and improved overall survival for patients with metastatic colorectal cancer. The study showed significant benefits with no increased incidence of serious side...

SourceMemorial Sloan Kettering Cancer Center·JournalNew England Journal of Medicine·DateSep 27, 2000

Olive oil seems to protect against cancer

A study analyzing data from 28 countries found that a diet rich in olive oil was associated with a decreased risk of bowel cancer. The researchers discovered that meat and fish consumption, particularly high amounts, increased the risk of the disease, whereas cereal and vegetable intake had a protective effect.

SourceBMJ Specialty Journals·JournalJournal of Epidemiology and Community Health·DateSep 18, 2000

Study shows that combined therapies increase life expectancy in patients with metastatic colorectal cancer

A new treatment approach combining traditional chemotherapy with medication delivered through an implanted pump has been found to significantly increase two-year survival rates and decrease tumor recurrence in patients with advanced colorectal cancer that has spread to the liver. The study, published in the New England Journal of Medic...

SourceMemorial Sloan Kettering Cancer Center·JournalNew England Journal of Medicine·DateDec 28, 1999

New England Journal Of Medicine Reports Calcium Supplements Help Prevent Polyp Recurrence; DMS Led Study

A multi-centered study led by Dartmouth Medical School found that supplementation with calcium can reduce the recurrence rate of large bowel adenomas in people with a history of these particular polyps. The findings suggest promising measures that are fairly simple and inexpensive to help prevent colorectal cancer.

SourceThe Geisel School of Medicine at Dartmouth·JournalNew England Journal of Medicine·DateJan 14, 1999

Study Links Colon Cancer To Diabetes Drug

A study published in Nature Medicine suggests that the diabetes drug troglitazone may increase the risk of colon cancer by activating the PPAR receptor, which promotes tumor formation in the colon. The study found that mice treated with troglitazone developed a significantly greater number of colon polyps than those not treated.

SourceHoward Hughes Medical Institute·JournalNature Medicine·DateSep 1, 1998